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Background: It is well known that hyperglycemia and elevated HbA1c level on admission
are poor prognostic factors in diabetic patients with acute myocardial infarction (AMI). but the
use of intensive therapy to target normal HbA1c level increased mortality and did not
significantly reduce major cardiovascular events in ACCORD Study. is the less than 6.0%
HbA1c level on admission safe in diabetic patients with AMI? The aim of this study was to
determine the contribution of HbA1c at admission on prognosis of AMI.
Methods: A total of 2,679 diabetic patients with AMI in KorMI registry between
January 2008 and August 2011. There are 1,360 ST segment elevation myocardial
infarction and 1319 non ST segment elevation myocardial infarction. Plasma HbA1c
levels were available for all patients. We categorized the patients according to HbA1c
level, Group I 6%, Group II 6. 1-month and 12-month major adverse cardiac event
(MACE) was defined as either all cause of death, myocardial infarction and any type of
revascularization.
Results: Less than 6.0% HbA1c Group I had a higher 1-month and 12-month MACE
than over the 6.0% HbA1c Group II. In multiple logistic regression analysis, less than
6.0% HbA1c was related to an increased risk of developing MACE (odds ratio 2.80, 95%
confidence interval 1.63-4.80, p0.001).
Conclusion: Less than 6.0% HbA1c on admission might be an important poor
prognostic factor in diabetic patients with AMI at 1-month and 12-month follow-up.
HbA1c<6.0% HbA1c>6.0%
Patient Number 201 2478
1 month MACE 29 (14.4%) 205 (8.3%) p0.01
12 month MACE 43 (21.4%) 322 (13.0%) p0.001
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Purpose: There is no evidence to apply a differentiated approach to the choice of
revascularization strategy for patients with ST-elevation myocardial infarction (STEMI)
and multivessel disease (MVD). Thirty-day and long-term outcomes of different strate-
gies of revascularization in a cohort of STEMI patients with MVD, depending on the
severity of coronary stenosis on a SYNTAX SCORE were analyzed.
Methods: Outcomes of different revascularization strategies in 227 STEMI patients in
the aspect of an objective assessment of the severity of coronary lesions on a SYNTAX
SCORE were studied. The first group consisted of patients who underwent multivessel
stenting (MS) strategy in the primary PCI (n  40), the second group consisted of
patients defined by staged revascularization (SR) (n 187). Each group was divided into
subgroups according to severity of coronary lesions on a SYNTAX SCORE: SYNTAX
 22 (moderate) and SYNTAX  23 (severe).
Results: Subgroups of patients with SYNTAX  23, as a group, MS, and SR group at
baseline were associated with decreased left ventricular ejection fraction compared with
subgroups SYNTAX  22 (p 0.05). In the SR group,as for 30 days and within 12
months observation was significantly more frequent need for non-target vessel
revascularization(non-TVR) compared with the group of MS, 13.3% vs 0, and 50.3% vs
15%, respectively (p 0.05). In 12 months observation SR group had combined
end-point (death  myocardial infarction  target vessel revascularization (TVR)) 23%
vs. 7.5% in the MS group (p 0.05). SYNTAX  23 in the SR group compared with
SYNTAX»  22 was associated with significantly greater frequency of death, 11.5% vs.
2.75% (p0.05) and combined end-point, 29.5% vs. 18.3% (p0.05), respectively for 12
months observation.
Conclusion: In a cohort of STEMI patients with MVD revealed the relationship
between severe coronary stenosis (SYNTAX  23) and a number of clinical and
angiographic parameters, in particular, is reflected in the frequency of adverse outcomes at
12 months of observation. The strategy of MS had satisfactory results at 12 months of
observation regardless of the severity of coronary lesions, whereas patients with SR group
(SYNTAX 23) showed worse outcomes compared with patients with moderate severity
of coronary lesions (SYNTAX  22).
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Objective: The aim of this study is to compare the efficacy and safety of prasugrel 60 mg
vs. clopidogrel 600 mg loading doses in patients undergoing primary PCI for acute
STEMI.
Background: There is ever increasing evidence to suggest that potent antiplatelet therapy
plays a crucial role in the management of patients with Acute Coronary syndromes
(ACS). Recent randomized trial demonstrated greater reduction in infarct size with
clopidogrel 600 mg vs. 300 mg loading doses in patients undergoing primary PCI for
STEMI. While the Triton TIMI 38 trial demonstrated superiority of prasugrel 60 mg to
clopidogrel 300 mg load in patients with ACS, to our knowledge there has never been a
head to head comparison between prasugrel 60 mg vs. clopidogrel 600 mg loading doses.
Methods: This was a retrospective observational study comparing patients presenting
with acute STEMI, who were treated with prasugrel 60 mg vs. clopidogrel 600 mg
loading doses. These were sequential patients based on a protocol driven change from
clopidogrel to prasugrel. The primary end point was the evaluation of infarct size, based
on peak CK and CK-MB elevation. Secondary end points include global discharge LVEF
and TIMI flow grade before and after PCI. Safety endpoint was in-hospital bleeding
complications.
Results: Mean age of the study subjects was 56 years, with 82% being males. There was no
statistically significant difference between the two groups in terms of infarct size. The peak CK
was 1442 1128 U/L in the prasugrel group (n38) vs. 1522 1467 U/L in the clopidogrel
group (n34) (p0.79). The peak CK-MB was 132 100 ng/ml in the prasugrel group vs.
123 117 ng/ml in the clopidogrel group (p0.73). Similarly, there were no significant
differences in the prespecified secondary end points and safety end point.
Conclusions: In patients undergoing primary PCI for acute STEMI, pretreatment with
prasugrel 60 mg vs. clopidogrel 600 mg was not associated with significant difference in
infarct size. These findings support the need for additional randomized trials to determine
the relative efficacy of these two different strategies in the acute STEMI population.
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